Post operative concurrent chemo-radiotherapy versus post-operative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
For patients who have undergone surgery for high-risk skin cancer of the head and neck, this study aims to determine whether there is a difference in time to loco-regional relapse (cancer coming back in the same area) between patients treated with concurrent chemo-radiotherapy (using the chemo drug Carboplatin) versus those participants who were treated with radiotherapy alone.
Primary Sponsor
Trans Tasman Radiation Oncology Group (TROG)
Final Accrual
321
Trial Chairperson
Professor Sandro Porceddu,
Princess Alexandra Hospital,
QLD
Clinical Trial Registration
Related Post
October 18, 2022
NINJA Radiation Therapy Trial participant tells his journey to treatment
The journey to becoming the 200th participant for the
September 6, 2022
The gift that kept on giving
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
